Extended-spectrum β-lactamase-producing organisms

Bush, 1995, A functional classification scheme for beta-lactamases and its correlation with molecular structure, Antimicrob Agents Chemother, 39, 1211, 10.1128/AAC.39.6.1211

Ambler, 1969, Chemical structure of bacterial penicillinases, Nature, 222, 24, 10.1038/222024a0

Jacoby, 2005, The new beta-lactamases, N Engl J Med, 352, 380, 10.1056/NEJMra041359

Jones, 2009, Characterization and sequence analysis of extended spectrum β-lactamase encoding genes from Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials, Antimicrob Agents Chemother, 53, 465, 10.1128/AAC.00883-08

Livermore, 2007, CTX-M: changing the face of ESBLs in Europe, J Antimicrob Chemother, 59, 165, 10.1093/jac/dkl483

Bonnet, 2004, Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes, Antimicrob Agents Chemother, 48, 1, 10.1128/AAC.48.1.1-14.2004

Reinert, 2007, Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline, J Antimicrob Chemother, 60, 1018, 10.1093/jac/dkm310

Hackel M, Badal R, Bouchillon S, et al. Extended-spectrum beta-lactamase production in Europe. In: Abstracts of the 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Barcelona, Spain, 2008.

Pitout, 2008, Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern, Lancet Infect Dis, 8, 159, 10.1016/S1473-3099(08)70041-0

Lewis, 2007, First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system, Antimicrob Agents Chemother, 51, 4015, 10.1128/AAC.00576-07

Drieux, 2008, Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: review and bench guide, Clin Microbiol Infect, 14, 90, 10.1111/j.1469-0691.2007.01846.x

Wiegand, 2007, Detection of extended-spectrum beta-lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures, J Clin Microbiol, 45, 1167, 10.1128/JCM.01988-06

Rodriguez-Bano, 2008, Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli, Arch Intern Med, 168, 1897, 10.1001/archinte.168.17.1897

Paterson, 2005, Extended-spectrum beta-lactamases: a clinical update, Clin Microbiol Rev, 18, 657, 10.1128/CMR.18.4.657-686.2005

Canton, 2008, Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe, Clin Microbiol Infect, 14, 144, 10.1111/j.1469-0691.2007.01850.x

Rodriguez-Bano, 2008, Faecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology, J Antimicrob Chemother, 62, 1142, 10.1093/jac/dkn293

Falagas, 2008, Clinical Microbiology and Infectious Diseases (ECCMID) – 18th European Congress. Drug resistance among Gram-negative and Gram-positive bacteria, IDrugs, 11, 409

Valverde, 2008, Complex molecular epidemiology of extended-spectrum beta-lactamases in Klebsiella pneumoniae: a long-term perspective from a single institution in Madrid, J Antimicrob Chemother, 61, 64, 10.1093/jac/dkm403

Nicolas-Chanoine, 2008, Extended-spectrum beta-lactamases in long-term-care facilities, Clin Microbiol Infect, 14, 111, 10.1111/j.1469-0691.2007.01862.x

Rodriguez-Bano, 2006, Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control, Clin Infect Dis, 42, 37, 10.1086/498519

Pfaller, 2006, Overview of the epidemiological profile and laboratory detection of extended-spectrum beta-lactamases, Clin Infect Dis, 42, S153, 10.1086/500662

Schwaber, 2007, Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis, J Antimicrob Chemother, 60, 913, 10.1093/jac/dkm318

Karageorgopoulos, 2008, Current control and treatment of multidrug-resistant Acinetobacter baumannii infections, Lancet Infect Dis, 8, 751, 10.1016/S1473-3099(08)70279-2

Matthaiou, 2008, Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case–control study, Crit Care Med, 36, 807, 10.1097/CCM.0B013E3181652FAE

Kim, 2008, Control of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae using a computer-assisted management program to restrict third-generation cephalosporin use, J Antimicrob Chemother, 62, 416, 10.1093/jac/dkn164

Peterson, 2008, Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam, Clin Microbiol Infect, 14, 181, 10.1111/j.1469-0691.2007.01864.x

Falagas, 2007, Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study, J Antimicrob Chemother, 60, 1124, 10.1093/jac/dkm356

Bin, 2006, Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli, Diagn Microbiol Infect Dis, 56, 351, 10.1016/j.diagmicrobio.2006.06.015

Goethaert, 2006, High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients, Clin Microbiol Infect, 12, 56, 10.1111/j.1469-0691.2005.01290.x

Zanetti, 2003, Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study, Antimicrob Agents Chemother, 47, 3442, 10.1128/AAC.47.11.3442-3447.2003

Paterson, 2001, Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, J Clin Microbiol, 39, 2206, 10.1128/JCM.39.6.2206-2212.2001

Wong-Beringer, 2002, Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime, Clin Infect Dis, 34, 135, 10.1086/324742

Bush, 1993, Kinetic interactions of tazobactam with beta-lactamases from all major structural classes, Antimicrob Agents Chemother, 37, 851, 10.1128/AAC.37.4.851

Payne, 1994, Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases, Antimicrob Agents Chemother, 38, 767, 10.1128/AAC.38.4.767

Burgess, 2003, Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period, Pharmacotherapy, 23, 1232, 10.1592/phco.23.12.1232.32706

Ambrose, 2003, Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program, Antimicrob Agents Chemother, 47, 1643, 10.1128/AAC.47.5.1643-1646.2003

Falagas, 2008, Antimicrobial resistance of Esherichia coli urinary isolates from primary care patients in Greece, Med Sci Monit, 14, CR75

Lee, 2006, Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates, J Antimicrob Chemother, 58, 1074, 10.1093/jac/dkl381

Lee, 2007, Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 beta-lactamases, J Antimicrob Chemother, 60, 410, 10.1093/jac/dkm215

Endimiani, 2004, Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin, Clin Infect Dis, 38, 243, 10.1086/380645

Paterson, 2004, Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases, Clin Infect Dis, 39, 31, 10.1086/420816

Bassetti, 2007, Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum beta-lactamase-producing organisms in an intensive care unit, J Antimicrob Chemother, 60, 433, 10.1093/jac/dkm180

Kim, 2002, Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia, J Hosp Infect, 52, 99, 10.1053/jhin.2002.1288

Kang, 2004, Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy, Antimicrob Agents Chemother, 48, 4574, 10.1128/AAC.48.12.4574-4581.2004

Falagas, 2009, Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline, Curr Drug Metab, 10, 13, 10.2174/138920009787048356

Kelesidis, 2008, Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies, J Antimicrob Chemother, 62, 895, 10.1093/jac/dkn311

Gales, 2006, Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001–2004), Clin Microbiol Infect, 12, 315, 10.1111/j.1469-0691.2005.01351.x

Falagas, 2008, Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin, Eur J Clin Microbiol Infect Dis, 27, 439, 10.1007/s10096-007-0456-4

Falagas, 2008, Fosfomycin: use beyond urinary tract and gastrointestinal infections, Clin Infect Dis, 46, 1069, 10.1086/527442

Garau, 2008, Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline, Clin Microbiol Infect, 14, 198, 10.1111/j.1469-0691.2007.01852.x

Livermore, 2008, Defining an extended-spectrum beta-lactamase, Clin Microbiol Infect, 14, 3, 10.1111/j.1469-0691.2007.01857.x

Giske, 2009, Redefining extended-spectrum beta-lactamases: balancing science and clinical need, J Antimicrob Chemother, 63, 1, 10.1093/jac/dkn444